Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer may look cheap with a ~7% yield, but tight free cash flow, patent cliffs, and limited growth raise downside risk. Read ...

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

Pfizer PFE faces patent expirations amounting to more than one quarter of 2024 revenue by 2028, and the 2023 acquisition of oncology-focused biotech Seagen boosted the firm’s invested capital base, ...

Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

Pfizer Inc. (NYSE:PFE) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported on January 20 that Britain ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...

Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.